(Q47905169)

6 February 2018

title

TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma (English)

1 reference

6 February 2018

1 reference

Jui Lan

1

1 reference

6 February 2018

Hsuan-Ying Huang

2

1 reference

6 February 2018

Sung-Wei Lee

3

1 reference

6 February 2018

Tzu-Ju Chen

4

1 reference

6 February 2018

Hui-Chun Tai

5

1 reference

6 February 2018

Han-Ping Hsu

6

1 reference

6 February 2018

Kwang-Yu Chang

7

1 reference

6 February 2018

Chien-Feng Li

8

1 reference

6 February 2018

publication date

30 July 2013

1 reference

6 February 2018

published in

Tumor Biology

1 reference

6 February 2018

volume

35

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

179-187

1 reference

6 February 2018

Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques.

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Controversies and challenges in the current management of nasopharyngeal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic varie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

HER-2 and topoisomerase II as predictors of response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Topoisomerase I and II activity in human breast, cervix, lung and colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Prognostication of soft tissue sarcomas based on chromosome 17q gene and protein status: evaluation of TOP2A, HER-2/neu, and survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Etoposide: four decades of development of a topoisomerase II inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1022-6

Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study

21 January 2018

1 reference

12 December 2020

Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer

1 reference

12 December 2020

Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells

1 reference

12 December 2020

A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples

1 reference

12 December 2020

Current and emerging treatment options for nasopharyngeal carcinoma.

1 reference

12 December 2020

Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma.

1 reference

12 December 2020

Nasopharyngeal carcinoma

1 reference

12 December 2020

Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function

1 reference

12 December 2020

HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil

1 reference

12 December 2020

10.1007/S13277-013-1022-6

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018